SurgiLight
This article was originally published in The Gray Sheet
Executive Summary
Two-for-one stock split for shareholders of record Jan. 25 is effective Jan. 27. The Orlando, Florida company is preparing an FDA investigational device exemption submission for use of its IR-3000 infrared laser system for presbyopia reversal. Trials are slated to start by mid-2000 (1"The Gray Sheet" Nov. 8, p. 19)
You may also be interested in...
SurgiLight Anticipating December IDE Filing For Infrared Ophthalmic Laser
SurgiLight, Inc. says it expects to submit an investigational device exemption in early December for its infrared laser system for vision correction.
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.